Amorphical Overview
Amorphical is a pioneering biotechnology company that develops and manufactures unique natural-based medicines and dietary supplements with high bio-availability, aiming at the improvement of calcium absorption and management, in tandem with balancing the body's acidity level (pH) derived by various biomedical conditions. These features are critical for maintaining health, repairing bone deficiencies, treating severe diseases, and aiding the development and strengthening of the body. Amorphical’s leading scientists succeeded in stabilizing and preserving a rare natural form of calcium used by blue crayfish to develop a unique nanometric substance called amorphous calcium carbonate, which helps improve people's health and quality of life.
Cumulative Funding Raised Over Time ($)
$1.0MJan 2020
$7.0MJan 2021
$8.8MMar 2010
$16.8MMar 2014
$25.6MMay 2016
Latest News
growth-positive
/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, today announced positive interim results from...
Amorphical, a biotechnology company, announced positive interim results from its ongoing open-label clinical trial for a nano-amorphous mineral-based therapy targeting moderate-to-severe Crohns disease. The investigational therapy, which aims to normalize the acidic microenvironment in the gut, showed significant clinical improvement and remission in patients. The trial, conducted in Israel, has enrolled 22 patients, with 17 providing open-label data. The results will inform Amorphicals future FDA regulatory strategy. The company is also advancing clinical programs in other conditions, supported by a robust patent portfolio and GMP-certified manufacturing infrastructure.
Product StageFDA approved/pending approval
growth-positive
/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, announced today the appointment of Eden Ben...
Amorphical, a biotechnology company specializing in nano-amorphous mineral-based pharmacologic agents, has appointed Eden Ben as its new CEO. The company is advancing its pipeline of disease-modifying therapies targeting conditions such as hypoparathyroidism, pancreatic cancer, osteoporotic fractures, and Crohns disease. With a focus on regulatory pathways in the U.S. and Europe, Amorphical is leveraging its proprietary technology to enhance bioavailability and optimize pH balance at the cellular level. The company is currently conducting a Phase 2 trial for hypoparathyroidism under FDA oversight and plans further studies for other conditions. The appointment of Ben is seen as a strategic move to accelerate the companys development and regulatory milestones.
Management ChangesProduct Stage
https://www.israelhayom.com/2022/06/13/israeli-shellfish-based-calcium-breakthrough-tested-in-space/
growth-positive
Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company | News Direct
Amorphical, an Israeli biotech company, has announced positive interim results from a Phase II clinical study of its COVID-19 treatment drug, AMOR-18. The study showed that patients hospitalized with moderate-to-severe COVID-19 who received AMOR-18 had a significantly reduced risk of ICU admission and mortality compared to those in the placebo group. None of the patients treated with AMOR-18 were transferred to the ICU or died, while 32% of the placebo group were transferred to the ICU and 10% died. The study is ongoing, and Amorphical plans to complete Phase II and proceed to Phase III. The company is also in the approval process to conduct a similar study in Brazil. AMOR-18 is based on Amorphicals unique amorphous calcium carbonate (ACC) technology.
Customers
growth-positive
אמורפיקל שמפיקה סידן מסרטנים כחולים יוצאת לגיוס של 30 מיליון דולר לפי שווי של 160 מיליון דולר
Israeli biotechnology company Amorphical has raised $30 million in a Series F funding round. The private placement includes existing and new investors, with UIC Group from Taiwan investing $1 million. In addition to the investment, UIC Group has signed an agreement to purchase Amorphicals products for $17.5 million and market them in Taiwan. The funds will be used for clinical trials of Amorphicals technology for treating secondary bone cancer. The company has also received a patent approval in the US for its amorphous calcium carbonate (ACC) technology, which is derived from blue algae and used in the treatment of blood cancer. Amorphical has raised a total of $23 million in previous funding rounds.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $28.3M |
| Last funding | $6M |
| Stage | F |
| Rounds | 6 |
| Investors | 2 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.amorphical.com |
Locations
HaHarash Street 11, Nes Ziyyona, Israel
Photos & Videos
3 item(s)
Amorphical Business
Business models
B2B, B2B2C
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Industrial ManufacturingDiscrete IndustriesAerospaceHealthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyHealthcarePatientsCore Technology
Materials & SubstancesTags (13)
pharmaceuticalssupplementsbiotechnologynutritioninvestorsprivate-investorspharma-companiesnovel-ingredientshospitalswellnessosteoporosiscancerspace-techGeographic Markets
TaiwanIsraelHong KongChinaAmorphical Financials
$28.3M
Total funding
Undisclosed
Capital raised
$6M
Last funding
F
Funding stage
6
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$1.0MJan 2020
$7.0MJan 2021
$8.8MMar 2010
$16.8MMar 2014
$25.6MMay 2016
Private Equity Funding
F Round
Jan 2021
$6M
F Round
Jan 2020
$1M
ICU group
E Round
May 2016
$8.8M
C Round
Mar 2014
$8M
A Round
Mar 2010
$1.8M
Undisclosed Investor(s)
Non-Equity Funding
GrantEvent
May 2013
$2.7M
Amorphical Lifecycle
Cumulative Funding Raised Over Time
$1.0MJan 2020
$7.0MJan 2021
$8.8MMar 2010
$16.8MMar 2014
$25.6MMay 2016
All Events
F Round
Jan 2021
$6M
F Round
Jan 2020
$1M
ICU group
E Round
May 2016
$8.8M
C Round
Mar 2014
$8M
A Round
Mar 2010
$1.8M
Undisclosed Investor(s)
GrantEvent
May 2013
$2.7M
Amorphical News
7 articles
growth-positive
/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, today announced positive interim results from...
Amorphical, a biotechnology company, announced positive interim results from its ongoing open-label clinical trial for a nano-amorphous mineral-based therapy targeting moderate-to-severe Crohns disease. The investigational therapy, which aims to normalize the acidic microenvironment in the gut, showed significant clinical improvement and remission in patients. The trial, conducted in Israel, has enrolled 22 patients, with 17 providing open-label data. The results will inform Amorphicals future FDA regulatory strategy. The company is also advancing clinical programs in other conditions, supported by a robust patent portfolio and GMP-certified manufacturing infrastructure.
Product StageFDA approved/pending approval
growth-positive
/PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, announced today the appointment of Eden Ben...
Amorphical, a biotechnology company specializing in nano-amorphous mineral-based pharmacologic agents, has appointed Eden Ben as its new CEO. The company is advancing its pipeline of disease-modifying therapies targeting conditions such as hypoparathyroidism, pancreatic cancer, osteoporotic fractures, and Crohns disease. With a focus on regulatory pathways in the U.S. and Europe, Amorphical is leveraging its proprietary technology to enhance bioavailability and optimize pH balance at the cellular level. The company is currently conducting a Phase 2 trial for hypoparathyroidism under FDA oversight and plans further studies for other conditions. The appointment of Ben is seen as a strategic move to accelerate the companys development and regulatory milestones.
Management ChangesProduct Stage
https://www.israelhayom.com/2022/06/13/israeli-shellfish-based-calcium-breakthrough-tested-in-space/
growth-positive
Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company | News Direct
Amorphical, an Israeli biotech company, has announced positive interim results from a Phase II clinical study of its COVID-19 treatment drug, AMOR-18. The study showed that patients hospitalized with moderate-to-severe COVID-19 who received AMOR-18 had a significantly reduced risk of ICU admission and mortality compared to those in the placebo group. None of the patients treated with AMOR-18 were transferred to the ICU or died, while 32% of the placebo group were transferred to the ICU and 10% died. The study is ongoing, and Amorphical plans to complete Phase II and proceed to Phase III. The company is also in the approval process to conduct a similar study in Brazil. AMOR-18 is based on Amorphicals unique amorphous calcium carbonate (ACC) technology.
Customers
growth-positive
אמורפיקל שמפיקה סידן מסרטנים כחולים יוצאת לגיוס של 30 מיליון דולר לפי שווי של 160 מיליון דולר
Israeli biotechnology company Amorphical has raised $30 million in a Series F funding round. The private placement includes existing and new investors, with UIC Group from Taiwan investing $1 million. In addition to the investment, UIC Group has signed an agreement to purchase Amorphicals products for $17.5 million and market them in Taiwan. The funds will be used for clinical trials of Amorphicals technology for treating secondary bone cancer. The company has also received a patent approval in the US for its amorphous calcium carbonate (ACC) technology, which is derived from blue algae and used in the treatment of blood cancer. Amorphical has raised a total of $23 million in previous funding rounds.
Investment
growth-positive
Amorphical signs China calcium capsule deal
Amorphical, a company that produces amorphous calcium capsules, has signed a marketing and distribution agreement with China Meheco in China. The company estimates revenue of a few million dollars in 2017 and $20-40 million in 2018 from the deal. Amorphical plans to expand its staff and is currently in a financing round at a company value of $110 million. The company is also conducting medical research on the use of amorphous calcium for the treatment of cancer. Amorphical was founded by CEO Yossi Ben, who discovered the technology while raising blue crabs.
PartnersExpand
growth-positive
Amorphical calcium absorption trial successful
Amorphical Ltd. has successfully completed a clinical trial of its new kind of calcium, amorphous calcium, which is absorbed better by the body than crystalline calcium. The trial found that patients absorption of amorphous calcium was double that of crystalline calcium. The company aims to develop a product as a nutritional supplement and medication. Amorphical has raised $1.2 million from private investors.
Investment
Amorphical Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 22 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
Amorphical Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 93/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 513562686 |
| Crunchbase | amorphical |
| Phone | +97286995333 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-09-05T00:00:00.000Z |
| Created | 2014-11-24T00:00:00.000Z |
| Claimed | Yes |